Urocortin has a high affinity for the corticotropin-releasing factor receptor type 2b (CRF-R2b). This study was conducted to reveal the role of CRF-R2b in blood vessels. CRF-R2b expressions were detected both in smooth muscle and endothelium from Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) aortas, and there was no significant difference between them. Urocortin reduced phenylephrine-induced contraction of aorta with endothelium dose-dependently in both rats. However, deendothelialization significantly but not completely (about 50%) reduced the vasodilation. The reduction of vasodilatory action of urocortin by deendothelialization was age-dependent in SHR. An adenylyl cyclase inhibitor, SQ22536, significantly inhibited urocortin-induced relaxation in denuded WKY and SHR aortas, while in preparations with endothelium, neither SQ22536 nor L-NMMA reduced the relaxation. However, simultaneous addition of both drugs significantly reduced the relaxation. In contrast to young rats (7-week-old), in aged rats (19-week-old), L-NMMA successfully reduced urocortininduced relaxation of aorta with endothelium. These results suggest that urocortin relaxes aorta at least partly via two signal pathways, that is, an increase in intracellular cAMP by binding to CRF-R2b expressed in smooth muscle cells and NO production from endothelium evoked by binding to the receptors expressed in endothelium and that aging increases the role of the latter system.
Introduction
Corticotropin-releasing factor (CRF) is a neuropeptide contributing to the regulation of neuroendocrine function, that is, hypothalamic-pituitary-adrenal axis and stress response in mammals. CRF receptor has two subtypes of CRF-R1 and CRF-R2. CRF-R1 exists in brain and pituitary and CRF-R2 in central and peripheral nerve systems and the circulatory system. CRF-R2 has been further categorized into two subtypes, a and b. Urocortin (41 amino acid polypeptide) was reported as a new member of the CRF family having higher affinity than CRF for the CRF receptor, especially high affinity for CRFR2b (1) . Urocortin-induced vasodilation has been observed in a variety of in vitro blood vessel preparations, that is, rat mesenteric, cerebral and femoral arteries (2) , rat aorta (3) , and rat basilar artery (4) .
Furthermore, it has been reported that urocortin has coronary vasodilation and positive inotropic effects in the isolated rat heart (5) . Although CRF-R2b was found in both vascular endothelial cells and smooth muscle cells, urocortin-induced vasodilation has been reported to be independent of endothelial cells (4) . Therefore, the role of CRF-R2b in endothelial cells has remained unknown.
The distensibility of the arterial system decreases with aging and hypertension (6) . As the major regulator of vascular homeostasis, the endothelium modulates the tone of the underlying vascular smooth muscle by releasing relaxing factors, including nitric oxide (NO). A defect in the production or activity of nitric oxide leads to endothelial dysfunction, signaled by impaired endothelium-dependent vasodilation. Aging may cause endothelial dysfunction, resulting in several cardiovascular disorders such as vasospasm, thrombus formation, and in turn, myocardial ischemia (7, 8) . The inci-dence of hypertension also increases during aging. The vascular mechanisms involved are unclear, but reduction of NO synthesis in endothelium may play an important role. Oxidative stress is one of the candidates of the cause of endothelial dysfunction (9) . NO production affected by aging may play a key role in several cardiovascular disorders.
The present study was conducted to investigate a role of CRF-R2b expressed in endothelial cells during vasorelaxation induced by urocortin using ring segments of thoracic aortas from WKY and SHR rats in various ages. The data in this report suggested that the mechanism of vasodilation evoked by urocortin involves endothelium-dependent NO production and endothelium-independent cAMP increases in smooth muscle cells and that the contribution of NO becomes more important with aging.
Materials and Methods
This study was approved by the Ethics Committee of Hirosaki University School of Medicine.
Materials
Rat urocortin was purchased from Peptide Institute (Osaka). L-Phenylephrine hydrochloride (phenylephrine) and N-monomethyl-L-arginine acetate (L-NMMA) were purchased from Wako (Osaka). SQ22536 was purchased from Calbiochem (San Diego, CA, USA). Carbamyl-bmethylcholine chloride (carbamyl choline) was purchased from Sigma (St. Louis, MO, USA).
Measurement of isometric contraction
After rats (WKY and SHR, 7 -19-week-old) were killed by ether anesthesia, the thoracic aorta was dissected, and connective tissues were carefully removed. The aorta was cut into round strips approximately 2 mm in length. The endothelium was removed by a glass stick. The strip was suspended in a 3-ml organ bath containing Tyrode solution of the following composition: 137 mM NaCl, 2.7 mM KCl, 1.1 mM MgCl 2 , 5.6 mM glucose, 1.8 mM CaCl 2 , 0.4 mM NaH 2 PO 4 , and 11.9 mM NaHCO 3 . The solution was gassed with 95% O 2 + 5% CO 2 with temperature maintained at 37°C. The tissues were left undisturbed for 1 h and then equilibrated for 30 min under a resting tension of 1 g. Isometric contraction was then measured by the transducer (UFER AP-5; Iwashiya, Kyoto). After the strip was contracted by adding phenylephrine (1 mM), whether it was dilated by carbamyl choline (10 mM) was checked twice in order to investigate the completeness of deendothelialization.
About 5 min after the strip was contracted by adding 1 m M phenylephrine for the third time, urocortin was added to the solution. SQ22536, an adenylyl cyclase inhibitor, was added 25 min before addition of phenylephrine. L-NMMA, a NOS inhibitor, was added 10 min before addition of phenylephrine.
Detection and measurement of mRNA expression of urocortin receptor CRF-R2b in intima and media of rat aortas The total RNA samples were extracted from intima and media of rat aortas with an RNeasy Kit (Qiagen, Chatsworth, CA, USA) according to manufacturer's protocol. The total RNA was treated with RNase-free DNase I (Life Technologies, Inc., Gaisethersburg, MD, USA) and reverse transcribed into cDNA using oligo (dT) 12-18 primer (Life Technologies). One microgram of total RNA was heated at 70°C for 10 min in 10 ml of H 2 O supplemented with 0.5 mg oligo (dT) 12-18 primer. The mixture was placed on ice, and cDNA synthesis was then performed by reverse transcription (RT) for 1 h at 37°C in a final volume of 20 m l of buffer (50 mM Tris-HCl pH 8.3, 75 mM KCl and 3 mM MgCl 2 ) supplemented with 0.5 mM of dNTPs (Life Technologies), 2.5 mM of DTT (Life Technologies), 2 U of RNase inhibitor (Toyobo, Osaka), and 200 U of M-MLV reverse transcriptase (Life Technologies). After the incubation, the cDNAs were heated to 72°C and then stored at -20°C until use for amplification by PCR. The expression of CRF-R2b was detected by PCR. The PCR products were separated by agarose (2.5%) gel electrophoresis, and stained with SYBR-green (Molecular Probe, Inc., Eugene, OR USA). Expression of the receptor mRNA was quantified by SYBR Green-real time PCR with ABI PRISM 7000 (Applied Biosystems, Foster, CA, USA) (10) . Primer sequences were as follows: CRFR2b, forward primer: CTGAGAAACAT CACGTGGTTCCT and reverse primer: GCGGCACCA GACCTCATT; G3PDH as an internal standard, forward primer: CGGATTTGGCCGTATTGG and reverse primer: CAATGTCCACTTTGTCACAAGAGAA. The PCR cycling conditions for both genes were 94°C for 30 s, 55°C for 20 s, and 72°C for 30 s.
The analysis of the PCR results was done using the D Ct value (Ct CRFR2 -Ct GAPDH ). Relative gene expression was obtained by DDCt methods (D Ct sample -D Ct calibrator ) for comparison of every unknown-sample gene expression level. The conversion between DDCt and relative gene expression levels is fold induction = -2 -DDCt .
Statistical analysis
All values are presented at means ± S.E.M. ANOVA with a Dunnett-type test for multiple comparisons against a control and Student's t-test was used. P<0.05 was considered significant.
Results

Expression of CRF-R2b
It has been reported that urocortin has a high affinity for CRF-R2b . The expression of CRF-R2b was analyzed by quantitative RT-PCR in media (vascular smooth muscle cells (VSMC)) and intima (endothelium cells (EC)) from WKY and SHR rat aortas ( Fig. 1 ). Messenger RNA for CRF-R2b was almost equally detected in both cell types of WKY and SHR. Quantification of mRNA expression of CRF-R2b was carried out by real time PCR. There was no significant difference between tissues and rat ages ( Table 1) .
Endothelium-dependent relaxation
Urocortin-induced relaxation was analyzed in isolated aortic ring preparations with or without endothelium prepared from WKY and SHR rats. After aortic rings were contracted by adding phenylephrine (1 mM), it was dilated by carbamyl choline (CCh, 10 mM) to check the completeness of endothelial denudation. CCh-induced relaxation was completely suppressed by denudation, but urocortin-induced relaxation was only partially suppressed by denudation, suggesting that urocortininduced relaxation is at least partly dependent on endothelium (Fig. 2) .
Because aging has been reported to be associated with an endothelium dysfunction (11 -13) , urocortin induced-relaxation was measured and compared in WKY and SHR rat aortic rings between the ages of 7 and 19 weeks (Fig. 3) . In WKY, removal of endothelium reduced urocortin-induced vasodilation to about half maximum for each age. In SHR, however, urocortininduced vasodilation was gradually reduced by aging to 10% at 19 weeks.
Effect of adenylyl cyclase inhibitor
Aortic rings without endothelium prepared from 7week-old WKY and SHR rats were immersed in various concentrations of urocortin (0.1, 0.3, and 1 mM) in the presence or absence of 100 mM SQ22536, an adenylyl cyclase inhibitor (Fig. 4) . Vasodilation was significantly inhibited by 100 mM SQ22536 in both rats. However, SQ22536 failed to inhibit the vasodilation in preparations with intact endothelium (Fig. 5 ).
Effect of NO synthase inhibitor
Because SQ22536 did not affect urocortin-induced relaxation in the endothelium-intact preparation, possible contribution of endothelium-derived NO to the relaxant response was investigated. Aortas with endothelium prepared from 7-week-old WKY and SHR rats were exposed to various concentrations of urocortin (0.1, 0.3, and 1 m M) in the presence or absence of 100 m M L-NMMA, a potent NO synthase inhibitor ( Fig. 6 ). Urocortin-induced vasodilation in 7-week-old WKY and SHR rat aortas with endothelium was not inhibited by 100 m M L-NMMA.
Aortas with endothelium prepared from 7-week-old WKY and SHR rats were exposed to various concentrations of urocortin (0.1, 0.3, and 1 m M) in the presence or absence of 100 mM L-NMMA and 100 mM SQ22536 (Fig. 7) . Urocortin-induced vasodilation in 7-week-old WKY and SHR rat aortas with endothelium were inhibited by 100 mM L-NMMA and 100 mM SQ22536.
In young WKY and SHR rats, urocortin-induced vasodilation appears to be mediated by both cAMP in vascular smooth muscle and NO production from endothelium. Aortas with endothelium prepared from 19-week-old WKY and SHR rats were exposed to various concentra-tions of urocortin (0.1, 0.3, and 1 m M) in the presence or absence of 100 mM L-NMMA (Fig. 8 ). L-NMMA remarkably inhibited the relaxation induced by urocortin. In old WKY and SHR rats, urocortin-induced vasodilation appears to be mediated by NO production from endothelium. However, SQ22536 failed to inhibit the vasodilation both in WKY and SHR rat aortas, suggesting the relatively minor role of cAMP-dependent relaxation of aortas from aged rats (data not shown). 
Discussion
It has been reported that urocortin is a potent, endothelium-independent dilator of WKY rat tail arteries, because denudation did not affect the vasodilation effect of urocortin (14) . However, the urocortin receptor CRF-R2b has been reported to be found in both vascular endothelial cells and smooth muscle cells (15) , which was also confirmed in this report. The role of CRF-R2b in endothelial cells is therefore not fully known. In contrast to the tail arteries, however, our observation indicates that relaxation of aorta from not only WKY but also SHR species of rats induced by urocortin is dependent on the intactness of endothelium. Removal of endothelium reduced the vasodilation up to about 50%.
These results suggest that urocortin receptor in endothelium may play some important role in the regulation of vascular tone.
A cyclic AMP-dependent protein kinase inhibitor, Rp-8-CPT-cAMPS, significantly reduced the vasodilation, suggesting an increase in cyclic AMP concentration evoked by urocortin (14) . Urocortin-induced vasodilation of isolated thoracic aorta without endothelium was significantly inhibited by SQ22536, an adenylyl cyclase inhibitor. Adenylyl cyclase activity in denuded aorta from both WKY and SHR rats was increased by urocortin in a concentration-dependent manner (K. Seya et al., our unpublished observation). These results suggest that urocortin relaxed vascular smooth muscle via an increase in intracellular cAMP concentration by binding to CRF-R2b expressed in vascular smooth muscle cells.
Nitric oxide is a potent vasodilator released from endothelium cells. In WKY and SHR rats, neither the NOS inhibitor L-NMMA nor SQ22536 inhibited urocortin-induced vasodilation in thoracic aorta with endothelium of young rats. Only in the presence of both L-NMMA and SQ22536, urocortin-induced relaxation was significantly reduced, suggesting that endotheliumdependent and -independent pathways can compensate for each other's functions. However, L-NMMA inhibited urocortin-induced vasodilation in thoracic aorta with endothelium of aged rats. Although it has been reported that the activity of NO synthase is reduced by aging (16), there was no significant change in NO synthase mRNA expression between 7-and 19-week-old rats (data not shown). These results suggest that in WKY and SHR rats, urocortin induces both endothelium-dependent and independent relaxation. Urocortin relaxes vascular smooth muscle via NO production from endothelium more than an increase in intracellular cAMP concentration by aging. The mechanisms underlying the vasodilator response to urocortin are different in each rat strain and each type of vessels used.
